Welcome to our dedicated page for Enveric Biosciences SEC filings (Ticker: ENVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enveric Biosciences filings document a biotechnology issuer focused on neuroplastogenic small-molecule drug candidates for psychiatric and neurological disorders. Its periodic and current reports address operating results, pipeline updates for EB-003 and related molecule series, intellectual-property matters, risk factors and the use of investor presentation materials in Regulation FD disclosures.
The company’s SEC record also covers capital-structure and governance matters, including registered direct and private placement financings, at-the-market offering registration, common stock, pre-funded warrants, Series G, H, I and J warrants, resale registration obligations, and Nasdaq-listed common stock. Proxy materials describe director elections, executive-compensation votes, auditor ratification, reverse stock split proposals and authorized-share proposals.
PASQUALONE FRANK reported acquisition or exercise transactions in this Form 4 filing.
Enveric Biosciences director Frank Pasqualone received a grant of restricted stock. He was awarded 18,518 shares of common stock at no cash cost under the company’s 2020 Long-Term Incentive Plan. These shares will vest over time according to the plan and his award agreement.
After this equity grant, Pasqualone directly holds 26,423 shares of Enveric Biosciences common stock. This filing reflects a compensation-related stock award rather than an open-market purchase or sale.
WEBB MICHAEL D reported acquisition or exercise transactions in this Form 4 filing.
Enveric Biosciences director Michael D. Webb received a grant of 18,518 shares of restricted common stock. The award was made under the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan as amended, with vesting governed by the plan and his restricted stock agreement.
These shares were granted at no cash cost per share and are compensation rather than an open-market purchase. Following this grant, Webb directly holds a total of 26,416 shares of Enveric Biosciences common stock, subject to the vesting terms of the award.
Schabacker Marcus reported acquisition or exercise transactions in this Form 4 filing.
Enveric Biosciences director Marcus Schabacker received a grant of 18,518 shares of restricted common stock under the company’s 2020 Long-Term Incentive Plan. The grant was awarded at no cash cost to him and will vest according to the plan and his award agreement. After this grant, he directly holds 26,418 shares of Enveric common stock.
Kegler George A. reported acquisition or exercise transactions in this Form 4 filing.
Enveric Biosciences director George A. Kegler received a grant of 18,518 shares of restricted common stock on June 1, 2026 under the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended. The grant was awarded at $0.0000 per share as equity compensation.
After this award, Kegler directly holds 26,418 shares of Enveric Biosciences common stock. The restricted shares will vest over time in line with the terms of the 2020 Long-Term Incentive Plan and his restricted stock award agreement.
DeWitt Sheila reported acquisition or exercise transactions in this Form 4 filing.
Enveric Biosciences director Sheila DeWitt received a stock grant reported on Form 4. She was granted 18,518 shares of restricted common stock at no cash cost, issued under Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan. After this award, she holds 26,306 common shares directly.
Enveric Biosciences, Inc. granted Chief Innovation Officer Peter J. Facchini 25,000 restricted stock units of common stock under its 2020 Long-Term Incentive Plan. Each unit will convert into one share of common stock as it vests, subject to continued employment.
One-fourth of the RSUs vest after one year, with an additional one-thirty-sixth vesting monthly until any remaining units vest on the fourth anniversary of grant. Following this award, Facchini holds 27,755 shares of common stock, adjusted for a prior 12-for-1 reverse stock split effective October 28, 2025.
Enveric Biosciences, Inc. reported two main developments. First, the board approved new standard forms of restricted stock unit (RSU) and restricted stock (RSA) award agreements under its 2020 Long-Term Incentive Plan. The RSUs vest over four years, while RSAs vest on specified dates, and both include change in control, forfeiture, and other customary terms for executives and directors.
Second, at the May 28, 2026 annual meeting, 991,828 shares were represented, equal to 52.54% of shares entitled to vote, establishing a quorum. Stockholders elected six directors and approved the advisory say-on-pay proposal with 569,552 votes for and 26,884 against. They extended board authority to implement a reverse stock split within a 1-for-5 to 1-for-15 range (793,344 for, 190,175 against), but voted against increasing authorized common shares to 5,000,000,000 (427,158 for, 555,147 against). The appointment of CBIZ CPAs P.C. as auditor for 2026 was ratified with 960,728 votes for and 19,347 against.
Enveric Biosciences: Schedule 13G/A showing significant warrant holdings by Lind affiliates and Jeff Easton. The filing reports 158,732 warrants held by Lind Global Fund III LP / Lind Global Partners III LLC (representing 7.76% of the class) and 161,232 warrants attributable to Jeff Easton (representing 7.87%). The ownership notes each include 79,366 Series G Warrants and 79,366 Series H Warrants; Jeff Easton is further associated with 2,500 warrants held by Lind Global Fund II. The warrants contain a conversion limitation that prevents conversion if doing so would cause beneficial ownership to exceed 9.99%.
Enveric Biosciences reported a net loss of $1.63M for the three months ended March 31, 2026, as it continues preclinical development of lead candidate EB-003 for mental health disorders. Operating expenses fell to $1.63M from $2.19M a year earlier, driven by lower R&D and G&A costs.
The company ended the quarter with $4.91M in cash and working capital of $4.91M, after raising $2.50M through a registered direct offering, concurrent private placement, and at-the-market (ATM) share sales. In April 2026 it added about $4.5M of net proceeds from another private placement and additional warrant exercises.
Despite these financings, Enveric has an accumulated deficit of $116.48M, negative operating cash flow of $2.26M in the quarter, and discloses that these factors raise substantial doubt about its ability to continue as a going concern over the next year. Management plans further capital raises and disciplined spending while advancing EB-003 toward IND-enabling studies.
Enveric Biosciences reported first quarter 2026 results and a corporate update centered on its lead neuroplastogenic candidate EB-003 and a strengthened intellectual property portfolio. EB-003 advanced through IND-enabling studies, with new preclinical data showing dual Gq and β-arrestin signaling at 5-HT2A and reduced conditioned fear in a PTSD model.
Net loss attributable to stockholders was $1.6 million, or $1.08 per basic and diluted share, for the quarter ended March 31, 2026, compared with a net loss of $2.2 million, or $14.58 per share, for the same period in 2025. Cash-on-hand was $4.9 million at March 31, 2026, and the company raised $2.8 million in gross proceeds during the quarter.
Subsequent financing events included a private placement of up to $13.9 million priced at-the-market under Nasdaq rules, with $5.0 million received at closing and up to approximately $8.9 million in potential additional warrant proceeds, plus $1.5 million from warrant exercises. As of May 15, 2026, cash was approximately $10.3 million, which management believes will fund EB-003 preclinical completion, an IND filing, and operations into the first quarter of fiscal 2027.